Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 2/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | STAT3 | P40763 | 2/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7705765 | 0.89 | CA12 (0.59) | CA12CA1CA2CA9CA14 | |
| SCHEMBL109451 | 0.84 | CA1 (0.61) | CA12CA1CA2CA9CA14 | |
| SCHEMBL28708208 | 0.81 | ELANE (0.38) | CA12CA1CA2CA9CA14 | |
| SCHEMBL11328309 | 0.81 | CYP1A2 (0.43) | CA12CA1CA2CA9CA14 | |
| Water SCHEMBL1464126 | 0.81 | TDP1 (0.62) | CA12CA1CA2CA9CA14 | |
| Hydrazine SCHEMBL10771056 | 0.80 | CA12 (0.62) | CA12CA1CA2CA9CA14 | |
| SCHEMBL28715351 | 0.80 | ELANE (0.34) | CA12CA1CA2CA9CA14 | |
| SCHEMBL4532351 | 0.78 | ELANE (0.60) | CA12CA1CA2CA9CA14 | |
| Hydrogen Peroxide SCHEMBL28425777 | 0.78 | TDP1 (0.64) | CA12CA1CA2CA9CA14 | |
| SCHEMBL260960 | 0.78 | TDP1 (0.64) | CA12CA1CA2CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 397 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117396477-A | Pyridyl-substituted oxoisoindoline compounds for the treatment of cancer | 百时美施贵宝公司 | 2024-01-12 | — | — | CN | claimed |
| US-11834532-B2 | Photoinitiators | IGH RESINS ITALIA S.R.L. (IT) | 2023-12-05 | — | — | US | claimed |
| EP-3902878-A1 | PHOTOINITIATORS | IGM Resins Italia S.r.l. (IT) | 2021-11-03 | — | — | EP | claimed |
| CN-113518805-A | Photoinitiator | 意大利艾坚蒙树脂有限公司 | 2021-10-19 | — | — | CN | claimed |
| WO-2020136522-A1 | PHOTOINITIATORS | IGM RESINS ITALIA S.R.L. (IT) | 2020-07-02 | — | — | WO | claimed |
| US-9102669-B2 | Substituted piperidinyl-pyridazinyl derivatives useful as SCD 1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-11 | — | — | US | claimed |
| US-20140371220-A1 | SUBSTITUTED PIPERIDINYL-PYRIDAZINYL DERIVATIVES USEFUL AS SCD 1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-18 | — | — | US | claimed |
| WO-2013085957-A1 | SUBSTITUTED PIPERIDINYL-PYRIDAZINYL DERIVATIVES USEFUL AS SCD 1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-06-13 | — | — | WO | claimed |
| US-20110281821-A9 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC. (US) | 2011-11-17 | — | — | US | claimed |
| JP-4673977-B2 | — | — | 2011-04-20 | — | — | JP | claimed |
| WO-2000059509-A1 | PHTHALAZINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2000-10-12 | — | — | WO | claimed |
| EP-0966456-A4 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | RES FOUNDATION OF (US) | 2000-07-26 | — | — | EP | claimed |
| EP-0966456-A1 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1999-12-29 | — | — | EP | claimed |
| US-5811452-A | ADMINISTERING WITH PACLITAXEL OR DOXORUBICIN | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1998-09-22 | — | — | US | claimed |
| WO-1998030553-A1 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1998-07-16 | — | — | WO | claimed |
| CN-1092780-A | Reduce and suppress the method for local asphyxia and reperfusion injury | LILLY CO ELI (US) | 1994-09-28 | — | — | CN | claimed |
| EP-0505413-B1 | BETA-LACTAM DERIVATIVES | ERBA CARLO SPA (IT) | 1994-08-31 | — | — | EP | claimed |
| EP-0505413-A1 | BETA-LACTAM DERIVATIVES. | ERBA FARMITALIA (IT) | 1992-09-30 | — | — | EP | claimed |
| WO-1991009036-A1 | BETA-LACTAM DERIVATIVES | FARMITALIA CARLO ERBA S.R.L. (IT) | 1991-06-27 | — | — | WO | claimed |
| US-4321118-A | Bis benzoyl sensitizers for photopolymerization or photo cross linking process and composition | CIBA-GEIGY CORPORATION (US) | 1982-03-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371220-A1 | SUBSTITUTED PIPERIDINYL-PYRIDAZINYL DERIVATIVES USEFUL AS SCD 1 INHIBITORS | SCD, SCD5, PLIN1 | CA12 4881/4885CA1 4883/4885CA2 4140/4885 |
| US-20110281821-A9 | Modulators of Mitotic Kinases | BUB1, BUB1B, CDK1 | CA12 4474/4885CA1 2849/4885CA2 1401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.